Literature DB >> 12858144

Strategies for treatment-resistant depression.

Christos Ballas1, Jeffrey P Staab, Dwight L Evans.   

Abstract

Approximately 30% of patients with major depression respond poorly to treatment with any given antidepressant regimen, and as many as 60% to 75% experience residual or recurrent symptoms. Strategies for improving response include extending the duration of each treatment beyond the usual 2-4 weeks, increasing the antidepressant dose, switching to another antidepressant, using two or more antidepressants together, and using adjunctive medications or other treatment modalities. Some of these strategies have strong support from clinical investigations while others are based more on clinical experience. This article reviews the risk factors for treatment resistance and provides strategies for improving treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12858144

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  3 in total

Review 1.  Neuropeptides in depression: role of VGF.

Authors:  Smita Thakker-Varia; Janet Alder
Journal:  Behav Brain Res       Date:  2008-10-15       Impact factor: 3.332

Review 2.  Implications of adult hippocampal neurogenesis in antidepressant action.

Authors:  Jessica E Malberg
Journal:  J Psychiatry Neurosci       Date:  2004-05       Impact factor: 6.186

3.  Study of the Role of CREB, BDNF, and VGF Neuropeptide in Long Term Antidepressant Activity of Crocin in the Rat Cerebellum.

Authors:  Bibi Marjan Razavi; Mahdieh Sadeghi; Khalil Abnous; Faezeh Vahdati Hasani; Hossein Hosseinzadeh
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.